Key takeaways
Cardiac biomarkers, such as hs-cTn and NT-proBNP, remain central to diagnosis and the management of later cardiovascular-kidney-metabolic (CKM) stages
Diabetes, chronic kidney disease (CKD), and obesity are independent risk factors for cardiovascular (CV) disease and represent earlier CKM stages; intervention could prevent disease progression
The liver must be part of integrated CKM syndrome management; cardiometabolic factors put individuals at risk for advanced fibrosis
Addressing CKM syndrome at proCardio
At the 14th international proCardio symposium, a unique, multidisciplinary group of experts gathered to address CKM syndrome.
Despite clinicians having access to precise diagnostics and disease-modifying therapies, premature CV mortality continues to rise.1 Modern healthcare cannot be reactive; it must shift toward proactive screening and early intervention.
A unified, multi-organ approach is needed to address CKM syndrome, which is linked to modern pandemics, such as obesity, diabetes, and CKD. This article summarizes the key discussions and learnings from proCardio 2026.
Cardiac biomarkers remain fundamental
High-sensitivity cardiac troponin (hs-cTn) assays revolutionized diagnostic protocols for acute coronary syndrome (ACS). New-generation high-sensitivity cardiac troponin (hs-cTn) assays continue to advance the analytical performance, with the goal to further improve diagnostic performance.2
Lori Daniels shared findings from the TSIX study program. REF-TSIX derived the assay-specific 99th percentile sex-specific cutoffs of the hs-cTnT Gen 6 assay.3 Approximately 70% of patients were successfully triaged via European Society of Cardiology (ESC) 0/1h and 0/2h rapid algorithms in PERFORM-TSIX, with its performance in a single-sample "one-and-done" rapid rule-out strategy also being investigated.4
Clinical decision support tools offer useful functionalities to support rapid triage, such as simplified hs-cTn interpretation and automated selection of an ESC 0/1, 0/2, or 0/3-hour protocol.5
Heart failure (HF) tends to be diagnosed after severe, acute symptoms appear, in hospital settings.6 This is frustrating considering the availability of cardiac biomarkers, such as N-terminal pro-B-type natriuretic peptide (NT-proBNP), which could be used in primary care settings.
Carolyn Lam and Mark Petrie presented SYMPHONY, which includes several studies investigating targeted screening of populations with risk factors for HF, using NT-proBNP testing and artificial intelligence (AI)-assisted portable echocardiography for early HF diagnosis.7
SYMPHONY is evaluating the capacity of this screening strategy to identify undiagnosed HF in the community setting, compared to usual care. While the results of TARTAN-HF (Scotland) were published recently,8 other studies are still in progress, including U-SCREEN (Sweden), MAPLE-CHF (Canada), EAGLE (USA), and MERMAID (Denmark), with further recruitment planned.7
New tools and ongoing research underline the efforts being made to diagnose ACS and HF as early and accurately as possible. But, there are opportunities to identify earlier stages of CKM, before clinical CV disease develops.
Identifying subclinical disease and CV risk
Cardiac biomarkers tell us when the heart is under stress or injured, but this is just one element of CV health. Other signs of disease or dysfunction can identify subclinical disease and contribute to defining CV risk.
Changes in blood pressure (BP) maintain hemostasis, but variability can also signal impaired regulation. A post-hoc analysis of the SPRINT study demonstrated an association between time in the BP target range and clinical outcomes; higher time in target range was associated with a reduced risk of major adverse CV events (MACE).9
A single or limited number of BP measurements can be misleading. As a result, cost-effective and convenient approaches for 24-hour monitoring are being explored; cuffless, wearable devices are available, but their accuracy needs to be assessed.
Ron Blankstein—Professor at Harvard Medical School—focused on a prevalent phenomenon, silent atherosclerosis.10 Precision imaging can identify and determine the intensity of plaques, to improve risk assessment and inform treatment approach.11 Combined with AI, the risk of infarction based on levels of stenosis can be determined.12 Rob Blankstein further explained that “imaging has become so prevalent in prevention guidelines because when we see the presence of plaque, that is the actual presence of disease.”
Diabetes is a prevalent risk factor
CV disease is the most prevalent cause of morbidity and mortality among diabetic patients,13 which demonstrates their close interconnectivity.
With diabetes prevalence rising and given that it is a major risk factor for HF, screening in these at-risk patients is essential.14,15 Kieran Docherty presented TARTAN-HF, one of the studies included in SYMPHONY, which enrolled patients with type 2 diabetes (T2D) and at least one other risk factor for HF.8
After 6 months, almost 25% of patients who were randomized to NT-proBNP screening were diagnosed with HF, compared to just 1% in the usual care group.8 When symptom burden was assessed in a blinded fashion, patients with unrecognized HF had significantly impaired health status versus those without HF.8
Ambarish Pandey presented STRONG-DM, an ongoing randomized controlled trial to assess a three-part intervention (primary care education, an electronic health record-based testing alert, and a virtual CKM consultation) versus usual care.16
In a single-center pilot study, almost 90% of people with diabetes whose primary care physician received the prompt to test NT-proBNP and hemoglobin A1c underwent screening, versus less than 5% with usual care.17 This identified high-risk patients who were prioritized for follow-up and treatment initiation as needed.17 STRONG-DM will evaluate the impact of the intervention on incident HF and all-cause death at 2 years in a larger population.16
TARTAN-HF and STRONG-DM support the need to closely monitor high-risk diabetic patients for the presence of unrecognized and preclinical HF, respectively, before symptoms arise. Annual check-ups are an opportunity to implement standardized HF screening with NT-proBNP.
CKD is associated with CV mortality
Like diabetes and CV disease, there is a bidirectional relationship between CKD and CV disease. CKD increases the risk of CV disease, while CV complications are the leading cause of death in patients with CKD.18
Urinary albumin-to-creatinine ratio (UACR) is a common test for CKD risk, but it can also be a powerful, dynamic CV risk marker. Despite being recommended for subclinical HF and established disease, Muthiah Vaduganathan—cardiologist at Brigham and Women's Hospital—warned that uptake is low.19
Various studies support the diagnostic value of UACR. A post hoc analysis demonstrated how UACR complements NT-proBNP for the prediction of future CV events.20 And when longitudinal changes in UACR were evaluated, a ≥30% increase in UACR was associated with hospitalization, MACE, and mortality.21 Muthiah Vaduganathan explained that "UACR is one biomarker that can provide clinical decision-making support that can actually move the needle."
Switching to a cardiac biomarker, Christopher DeFilippi discussed the elevation of hs-cTn above the 99th percentile in patients with CKD, which is a problem in acute care.23,23
A study in the chronic renal insufficiency cohort showed that elevated baseline hs-cTnT has prognostic value, with increasing levels associated with higher incident HF.24 However, serial 2-hour changes could help to overcome ambiguity in acute care; deltas of ≥20 ng/L or ≥30 ng/L achieved positive predictive values of 86% and 88%, respectively.25
These data shed further light on the bidirectional relationship between CKD and CV disease, and support the combined use of associated biomarkers.
Obesity is more than BMI
Going back to physiology, obesity causes dysfunction.26 When adipose tissues become dysfunctional, they secrete proinflammatory and prooxidative adipokines that damage arterial, cardiac, and kidney tissues.26
As Jennifer Green—Professor of Medicine at Duke University—highlighted, “excess and dysfunctional adipose tissue really represents the CKM entry point... We may know that but don’t act on it in a consistent fashion.”
Abnormal body mass index (BMI) is commonly used to define obesity, but it does not tell the full story. Two individuals with similar BMIs can have diverse metabolic profiles and CKM risk, depending on fat distribution and dysfunction.27 Alternative measures, such as metabolic score for visceral fat (METS-VF) and waist-to-height ratio, could provide greater prognostic value.
To identify the causes of obesity, tools such as the Check causes obesity questionnaire can provide a personalized summary of key drivers of weight gain.28 This can support the decision to start treatment of obesity, which must be individualized to account for the unique responses seen in one patient to the next.
Lee Kaplan—Associate Professor of Medicine at Harvard Medical School—remarked that “this field has suffered from a lack of research, perhaps because it was seen as a behavioral disease.”
Obesity is associated with more than 200 complications,29 meaning there is an opportunity to flip the traditional approach. Regular screening of obese patients can enable early intervention before CKM syndrome progresses.
Adding the liver to CKM syndrome
A healthy liver is needed for a healthy heart, vasculature, and kidneys;30 hence, Juan Pablo Frías argued that the liver should be part of integrated CKM care.
Liver fibrosis is the strongest predictor of both liver-related and CV adverse outcomes. The Fibrosis-4 (FIB-4) index is recommended to estimate the extent of fibrosis in at-risk patients, including those with T2D, or obese individuals with at least one other cardiometabolic risk factor.31
The relevance of liver inflammation and injury to CV disease is further highlighted by the design of clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) therapies. These include liver and metabolic outcomes, but they will also go on to assess CV outcomes.
Therefore, it is important to recognize the interconnectivity between the liver and CKM syndrome. Liver health should be part of integrated management, and it can be assessed non-invasively using existing tests.
Reflecting on proCardio 2026
Having explored the breadth of CKM, or cardiovascular-kidney-liver-metabolic (CKLM), syndrome, a holistic approach could maximize the potential of this golden era of cardiometabolic medicine. A multitude of tools and technologies exist, the challenge now is to combine and implement them effectively.
By shifting from hospital- to community-based care, and moving toward a proactive, preventive approach, we can get ahead of CKM syndrome; a multi-organ approach can underpin early identification and intervention.
References:
Hasani WSR, et al. The global estimate of premature cardiovascular mortality: a systematic review and meta-analysis of age-standardized mortality rate. BMC Public Health. 2023;23(1):1561.
F. Hoffmann-La Roche Ltd. Elecsys® Troponin T hs Gen 6. Method Sheet.(V4.0). 2026.
Daniels LB, et al. Impact of IFCC healthy reference population criteria on TnT hs Gen 6 99th percentile URLs: REF-TSIX. Poster presented at ESC Congress, 28–31 August 2026. Munich, Germany.
F. Hoffmann-La Roche Ltd. Data on file.
navify®. navify® Algorithms, Chest Pain Triage algorithm. [cited 2026 Nov 6]. Available from: https://navify.roche.com/marketplace/products/algorithms/navify-algorithms-chest-pain-triage. .
Alliance for Heart Failure. Primary Care: A call to action. Available from: https://allianceforheartfailure.org/heart-failure-being-overlooked-in-primary-care-warns-the-alliance-for-heart-failure/. [cited 2026 Nov 6].
clinicaltrials.gov. NCT05919342. [cited 2026 Nov 6]. Available from: https://clinicaltrials.gov/study/NCT05919342?term=NCT05919342&rank=1.
Taylor-Sweet, D, et al. Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF). JACC. 2026;88(15):1764–76.
Li M, et al. Association Between Systolic Blood Pressure Time in Target Range Indices and Adverse Cardiovascular Outcomes. JACC Adv. 2024;3(11):101350.
Bundgaard H, et al. Prevalence of Silent Atherosclerosis across Adult Life. N Engl J Med. 2026.
Henein MY, et al. Coronary Atherosclerosis Imaging. Diagnostics (Basel). 2020;10(2):65.
Sperti M, et al. Artificial Intelligence-based Approaches for Characterizing Plaque Components From Intravascular Optical Coherence Tomography Imaging: Integration Into Clinical Decision Support Systems. Rev Cardiovasc Med. 2025;26(7):39210.
Matheus AS, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013:653789.
Elendu C, et al. Heart failure and diabetes: Understanding the bidirectional relationship. Medicine (Baltimore). 2023;102(37):e34906.
Pop-Busui R, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670–90.
Subramanian V, et al. Screening and Treatment Using a Risk-Based Approach With NT-proBNP Guidance in Diabetes Mellitus: The STRONG-DM Pilot Study. J Am Coll Cardiol HF. 2026;14(10).
clinicaltrials.gov. NCT06593327. [cited 2026 Nov 6]. Available from: https://clinicaltrials.gov/study/NCT06593327.Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3(3):99–104.
Barzilay JI, Farag YMK, Durthaler J. Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease. J Am Heart Assoc. 2024;13(2):e030131.
F. Hoffmann-La Roche Ltd. Data on file.
F. Hoffmann-La Roche Ltd. Data on file.
deFilippi CR, Herzog CA. Interpreting Cardiac Biomarkers in the Setting of Chronic Kidney Disease. Clin Chem. 2017;63(1):59–65.
Miller-Hodges E, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome. Circulation. 2018;137(5):425–35.
Bansal N, et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2015;26(4):946–56.
Knott JD, et al. Diagnosis of acute myocardial infarction in patients with renal failure using high-sensitivity cardiac troponin T. Eur Heart J Acute Cardiovasc Care. 2024;13(7):546–58.
Su X, Peng D. Emerging functions of adipokines in linking the development of obesity and cardiovascular diseases. Mol Biol Rep. 2020;47(10):7991–8006.
Tanasescu MD, et al. Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Diagnostics (Basel). 2025;15(23):3025.
Check Causes Obesity. Understanding your weight. [cited 2026 Nov 6]. Available from: https://www.checkcausesobesity.com/.Yuen MMA. Health Complications of Obesity: 224 Obesity-Associated Comorbidities from a Mechanistic Perspective. Gastroenterol Clin North Am. 2023;52(2):363–80.
Luong TV, et al. Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease. World J Cardiol. 2025;17(7):107751.
European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024;67(11):2375–92.